证券代码：688139 证券简称：海尔生物 公告编号：2025-042 青岛海尔生物医疗股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 青岛海尔生物医疗股份有限公司（以下简称"公司"）将于 2025 年 8 月 27 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 08 月 28 日（星期四） 13:00-14:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 会议召开时间：2025 年 08 月 28 日(星期四)下午 13:00-14:00 会议召开地点：上海证券交易所上证 ...

西藏日喀则市桑珠孜区纳尔乡芝萨村卫生室里，村医索朗丹增操作着一台平板电脑，他告诉记者："获 取医疗技术支持、调取各种数据，只需要在平板电脑上操作。" 这得益于山东青岛援助日喀则市桑珠孜区打造的智慧医共体项目。青岛市第十批援藏干部人才组通过购 买青岛海尔生物医疗股份有限公司的企业服务，引进5G、大数据、AI等技术，打通区、乡、村三级医 疗数据，"织成健康信息'一张网'，构建'防、筛、诊、治、管、康'全周期健康管理闭环，开启桑珠孜 区'基层首诊、双向转诊、急慢分治、上下联动'的医疗服务新格局。"桑珠孜区卫生健康委主任次仁卓 嘎说。 建立群众健康档案，摸清健康底数 芝萨村村口有一座青岛援建的崭新二层小楼，这是村里的卫生室，在这里工作的两名村医是村民健康的 守护者。 89岁的南加是村里最年长的老人，也是索朗丹增牵挂的对象。每个月，他都会拿起"智能书包"和平板电 脑，上门为老人提供健康服务。包里装着血压计等，平板电脑里有老人的健康资料。 走进大门，他一边和老人寒暄，一边从包里拿出血压计。"这两个月血压变化不大，咱们还要继续保持 健康生活习惯，不要吃太多油盐。"量完血压，索朗丹增细细叮嘱。 随后，他用平板电脑详细记录检测 ...

Core Viewpoint - The medical nebulizer industry is experiencing significant growth driven by the aging population and the increasing prevalence of chronic respiratory diseases, with the market size in China projected to reach 4.281 billion yuan by 2024, reflecting an 11.4% year-on-year increase [1][14]. Industry Overview - Medical nebulizers are devices that convert liquid medication into aerosol particles for inhalation, primarily used to treat various respiratory diseases [3]. - The main types of nebulizers include compressed air nebulizers, ultrasonic nebulizers, and mesh nebulizers, each with distinct mechanisms and applications [4][5]. Market Dynamics - The market for medical nebulizers is expected to grow due to the rising number of healthcare institutions, which reached 1,093,600 in China by the end of 2024, a 2.13% increase year-on-year [12]. - The production of medical nebulizers in China is also on the rise, with an expected output of 22.37 million units in 2024, marking a 12.6% increase [18]. Competitive Landscape - The market features numerous participants, including both international brands like Omron and Philips, and domestic companies such as Yuyue Medical and Haier Medical, which are enhancing their competitiveness through R&D and quality improvements [20]. Product Segmentation - Compressed nebulizers dominate the market with a 78% share due to their efficiency, while ultrasonic nebulizers hold a smaller share of 3%, and mesh nebulizers have gained traction with a 19% market share [16]. Regulatory Environment - The Chinese government is actively promoting the development of the medical nebulizer industry through various policies aimed at enhancing innovation and regulatory frameworks [7]. Future Trends - The industry is moving towards precision medication delivery, smart nebulizers for remote monitoring, and portable, eco-friendly designs to enhance user experience [26][27][28].

Group 1 - The core viewpoint of the news highlights Haier Biomedical's stock performance, with a closing price of 34.33 yuan, an increase of 2.85%, and a rolling PE ratio of 32.17, marking a new low in 88 days, with a total market value of 10.915 billion yuan [1] - As of March 31, 2025, Haier Biomedical has 12,793 shareholders, a decrease of 453 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Haier Biomedical focuses on providing comprehensive digital solutions for life sciences and healthcare, targeting pharmaceutical companies, research institutions, hospitals, and public health organizations [2] - The company offers a wide range of products including low-temperature storage boxes, automated biological sample storage libraries, and various laboratory automation equipment, enhancing its innovation capabilities in life sciences and medical fields [2] - In 2022, Haier Biomedical received several prestigious awards and certifications, including the National Postdoctoral Research Workstation and the China Industrial Award, reflecting its growing strength in scientific and technological innovation [2] Group 3 - In the latest quarterly report for Q1 2025, Haier Biomedical reported an operating income of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, a year-on-year decrease of 19.88%, with a gross profit margin of 48.35% [3] - The company ranks 63rd in the medical device industry based on its PE ratio, which is significantly lower than the industry average of 56.56 and the median of 39.76 [3]

Group 1: Share Buyback Overview - The company approved a share buyback plan on January 13, 2025, allowing the repurchase of shares using its own funds through the Shanghai Stock Exchange, with a maximum price of 50 CNY per share and a total fund amount between 100 million CNY and 200 million CNY [1] - The buyback period is set for 12 months from the approval date [1] Group 2: Price Adjustment - Following the annual equity distribution in 2024, the maximum buyback price was adjusted to 49.5367 CNY per share starting June 6, 2025 [2] Group 3: Buyback Progress - As of July 31, 2025, the company had repurchased a total of 1,845,488 shares, representing 0.5804% of the total share capital, with a total expenditure of approximately 59.25 million CNY [3] - The highest and lowest prices for the repurchased shares were 34.69 CNY and 29.86 CNY, respectively [3] Group 4: Compliance and Disclosure - The company will adhere to relevant regulations and will make buyback decisions based on market conditions, ensuring timely disclosure of progress to investors [4]

Group 1 - The company has approved a share repurchase plan to buy back its issued A-shares using its own funds through the Shanghai Stock Exchange, with a maximum repurchase price of 50 RMB per share and a total repurchase amount between 100 million RMB and 200 million RMB within 12 months [2][5] - Following the annual equity distribution in 2024, the maximum repurchase price was adjusted to 49.5367 RMB per share starting June 6, 2025 [3] - As of July 31, 2025, the company has repurchased a total of 1,845,488 shares, accounting for 0.5804% of the total share capital, with a total expenditure of approximately 59.25 million RMB [4] Group 2 - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations regarding the progress of the share repurchase [6]

证券日报网讯 8月1日晚间，海尔生物发布公告称，截至2025年7月31日，公司通过上海证券交易所交易 系统以集中竞价交易方式累计回购公司股份1，845，488股，占公司总股本317，952，508股的比例为 0.5804%。 ...

格隆汇8月1日丨海尔生物(688139.SH)公布，截至2025年7月31日，公司通过上海证券交易所交易系统以 集中竞价交易方式累计回购公司股份184.55万股，占公司总股本的比例为0.5804%，回购成交的最高价 为34.69元/股，最低价为29.86元/股,支付的资金总额为人民币5925.34万元（不含交易费用）。 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-041 二、回购股份的进展情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/14 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 1 月 13 | 月 | 14 | 日~2026 | 年 | 1 | 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 1,845,488股 | | | | | | | | 累计已回购股数占总股本比例 | 0.5804% | | | | | | | | 累计已回购金额 | 59, ...

格隆汇8月1日丨海尔生物(688139.SH)公布，截至2025年7月31日，公司通过上海证券交易所交易系统以 集中竞价交易方式累计回购公司股份184.55万股，占公司总股本的比例为0.5804%，回购成交的最高价 为34.69元/股，最低价为29.86元/股,支付的资金总额为人民币5925.34万元（不含交易费用）。 ...